Literature DB >> 34035778

Insights on the Potential Use of Potassium-Competitive Acid Blockers in Erosive Esophagitis.

Colin W Howden1.   

Abstract

Entities:  

Year:  2021        PMID： 34035778      PMCID： PMC8132630     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.

Authors:  Hirota Miyazaki; Ataru Igarashi; Toshihisa Takeuchi; Lida Teng; Akihito Uda; Hisato Deguchi; Kazuhide Higuchi; Toshiro Tango
Journal:  J Gastroenterol Hepatol       Date:  2019-04-11       Impact factor: 4.029

2.  Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.

Authors:  Jung Sunwoo; Sang Chun Ji; Jaeseong Oh; Mu Seong Ban; Ji Yeon Nam; Bongtae Kim; Geun Seog Song; Kyung-Sang Yu; In-Jin Jang; SeungHwan Lee
Journal:  Aliment Pharmacol Ther       Date:  2020-11-01       Impact factor: 8.171

3.  Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Authors:  Kiyoshi Ashida; Katsuhiko Iwakiri; Naoki Hiramatsu; Yuuichi Sakurai; Tetsuharu Hori; Kentarou Kudou; Akira Nishimura; Eiji Umegaki
Journal:  World J Gastroenterol       Date:  2018-04-14       Impact factor: 5.742

4.  Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Authors:  Yinglian Xiao; Shutian Zhang; Ning Dai; Guijun Fei; Khean-Lee Goh; Hoon Jai Chun; Bor-Shyang Sheu; Chui Fung Chong; Nobuo Funao; Wen Zhou; Minhu Chen
Journal:  Gut       Date:  2019-08-13       Impact factor: 23.059

5.  Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.

Authors:  K Ashida; Y Sakurai; T Hori; K Kudou; A Nishimura; N Hiramatsu; E Umegaki; K Iwakiri
Journal:  Aliment Pharmacol Ther       Date:  2015-11-11       Impact factor: 8.171

6.  A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.

Authors:  Katsuhiko Iwakiri; Yuuichi Sakurai; Madoka Shiino; Hiroyuki Okamoto; Kentaro Kudou; Akira Nishimura; Naoki Hiramatsu; Eiji Umegaki; Kiyoshi Ashida
Journal:  Therap Adv Gastroenterol       Date:  2017-04-25       Impact factor: 4.409
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.